Bacteriological and clinical studies on meropenem in the pediatric field

H. Akita, Y. Sato, S. Iwata, Y. Nitta, T. Yokota, K. Sunakawa

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Bacteriological and clinical studies have been performed on meropenem (MEPM, SM-7338), a newly developed carbapenem antibiotic, in the pediatric field. 1. Antibacterial activities of MEPM against 24 clinical isolates were determined. MEPM showed excellent activity against Gram-positive bacteria including Staphylococcus aureus and Gram-negative bacteria, especially Escherichia coli and Branhamella catarrhalis. Against Haemophilus influenzae, MEPM had a higher activity than imipenem and flomoxef, but had a lower activity than piperacillin and cefoperazone. 2. Clinical efficacies of MEPM were evaluated in 32 cases with bacterial infections. A poor efficacy was observed in 1 patient with phlegmon but excellent or good efficacies were obtained in other 31 patients with tonsillitis (1), pneumonia (17), UTI (12), or SSSS (1). The overall efficacy rate was 96.9%. All strains except 1 of S. aureus were eradicated by the administration of MEPM, and a high eradication rate of 95.8% (23 out of 24 strains) was obtained. 3. No side effects were obsereved in 35 evaluated cases. As abnormal laboratory test results, elevated GOT, elevated GPT, eosinophilia and neutropenia were noted in 4, 4, 4 and 2 patients, respectively. 4. Influences on blood coagulation parameters were studied. PIVKA II was elevated upon administration of MEPM in some cases, but no changes in ATT, TT, HPT or Fbg were observed during the treatment. Based on the above results, it has been concluded that MEPM is a safe and effective drug to use in the treatment of pediatric infections. The usual recommended dosage and administration should be 10 to 20 mg/kg of MEPM at a time, using intravenous drip infusion, 3 times a day.

Original languageEnglish
Pages (from-to)744-755
Number of pages12
JournalJapanese Journal of Antibiotics
Volume45
Issue number6
Publication statusPublished - 1992
Externally publishedYes

Fingerprint

meropenem
Intravenous Infusions
Pediatrics
Staphylococcus aureus
Cefoperazone
Moraxella (Branhamella) catarrhalis
Tonsillitis
Piperacillin
Carbapenems
Cellulitis
Imipenem
Haemophilus influenzae
Eosinophilia
Gram-Positive Bacteria
Blood Coagulation
Neutropenia
Gram-Negative Bacteria
Bacterial Infections
Pneumonia
Escherichia coli

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Akita, H., Sato, Y., Iwata, S., Nitta, Y., Yokota, T., & Sunakawa, K. (1992). Bacteriological and clinical studies on meropenem in the pediatric field. Japanese Journal of Antibiotics, 45(6), 744-755.

Bacteriological and clinical studies on meropenem in the pediatric field. / Akita, H.; Sato, Y.; Iwata, S.; Nitta, Y.; Yokota, T.; Sunakawa, K.

In: Japanese Journal of Antibiotics, Vol. 45, No. 6, 1992, p. 744-755.

Research output: Contribution to journalArticle

Akita, H, Sato, Y, Iwata, S, Nitta, Y, Yokota, T & Sunakawa, K 1992, 'Bacteriological and clinical studies on meropenem in the pediatric field', Japanese Journal of Antibiotics, vol. 45, no. 6, pp. 744-755.
Akita H, Sato Y, Iwata S, Nitta Y, Yokota T, Sunakawa K. Bacteriological and clinical studies on meropenem in the pediatric field. Japanese Journal of Antibiotics. 1992;45(6):744-755.
Akita, H. ; Sato, Y. ; Iwata, S. ; Nitta, Y. ; Yokota, T. ; Sunakawa, K. / Bacteriological and clinical studies on meropenem in the pediatric field. In: Japanese Journal of Antibiotics. 1992 ; Vol. 45, No. 6. pp. 744-755.
@article{ac2a303ecf8b4778af13b22063295a93,
title = "Bacteriological and clinical studies on meropenem in the pediatric field",
abstract = "Bacteriological and clinical studies have been performed on meropenem (MEPM, SM-7338), a newly developed carbapenem antibiotic, in the pediatric field. 1. Antibacterial activities of MEPM against 24 clinical isolates were determined. MEPM showed excellent activity against Gram-positive bacteria including Staphylococcus aureus and Gram-negative bacteria, especially Escherichia coli and Branhamella catarrhalis. Against Haemophilus influenzae, MEPM had a higher activity than imipenem and flomoxef, but had a lower activity than piperacillin and cefoperazone. 2. Clinical efficacies of MEPM were evaluated in 32 cases with bacterial infections. A poor efficacy was observed in 1 patient with phlegmon but excellent or good efficacies were obtained in other 31 patients with tonsillitis (1), pneumonia (17), UTI (12), or SSSS (1). The overall efficacy rate was 96.9{\%}. All strains except 1 of S. aureus were eradicated by the administration of MEPM, and a high eradication rate of 95.8{\%} (23 out of 24 strains) was obtained. 3. No side effects were obsereved in 35 evaluated cases. As abnormal laboratory test results, elevated GOT, elevated GPT, eosinophilia and neutropenia were noted in 4, 4, 4 and 2 patients, respectively. 4. Influences on blood coagulation parameters were studied. PIVKA II was elevated upon administration of MEPM in some cases, but no changes in ATT, TT, HPT or Fbg were observed during the treatment. Based on the above results, it has been concluded that MEPM is a safe and effective drug to use in the treatment of pediatric infections. The usual recommended dosage and administration should be 10 to 20 mg/kg of MEPM at a time, using intravenous drip infusion, 3 times a day.",
author = "H. Akita and Y. Sato and S. Iwata and Y. Nitta and T. Yokota and K. Sunakawa",
year = "1992",
language = "English",
volume = "45",
pages = "744--755",
journal = "The Journal of antibiotics. Ser. B",
issn = "0368-2781",
publisher = "Japan Antibiotics Research Association",
number = "6",

}

TY - JOUR

T1 - Bacteriological and clinical studies on meropenem in the pediatric field

AU - Akita, H.

AU - Sato, Y.

AU - Iwata, S.

AU - Nitta, Y.

AU - Yokota, T.

AU - Sunakawa, K.

PY - 1992

Y1 - 1992

N2 - Bacteriological and clinical studies have been performed on meropenem (MEPM, SM-7338), a newly developed carbapenem antibiotic, in the pediatric field. 1. Antibacterial activities of MEPM against 24 clinical isolates were determined. MEPM showed excellent activity against Gram-positive bacteria including Staphylococcus aureus and Gram-negative bacteria, especially Escherichia coli and Branhamella catarrhalis. Against Haemophilus influenzae, MEPM had a higher activity than imipenem and flomoxef, but had a lower activity than piperacillin and cefoperazone. 2. Clinical efficacies of MEPM were evaluated in 32 cases with bacterial infections. A poor efficacy was observed in 1 patient with phlegmon but excellent or good efficacies were obtained in other 31 patients with tonsillitis (1), pneumonia (17), UTI (12), or SSSS (1). The overall efficacy rate was 96.9%. All strains except 1 of S. aureus were eradicated by the administration of MEPM, and a high eradication rate of 95.8% (23 out of 24 strains) was obtained. 3. No side effects were obsereved in 35 evaluated cases. As abnormal laboratory test results, elevated GOT, elevated GPT, eosinophilia and neutropenia were noted in 4, 4, 4 and 2 patients, respectively. 4. Influences on blood coagulation parameters were studied. PIVKA II was elevated upon administration of MEPM in some cases, but no changes in ATT, TT, HPT or Fbg were observed during the treatment. Based on the above results, it has been concluded that MEPM is a safe and effective drug to use in the treatment of pediatric infections. The usual recommended dosage and administration should be 10 to 20 mg/kg of MEPM at a time, using intravenous drip infusion, 3 times a day.

AB - Bacteriological and clinical studies have been performed on meropenem (MEPM, SM-7338), a newly developed carbapenem antibiotic, in the pediatric field. 1. Antibacterial activities of MEPM against 24 clinical isolates were determined. MEPM showed excellent activity against Gram-positive bacteria including Staphylococcus aureus and Gram-negative bacteria, especially Escherichia coli and Branhamella catarrhalis. Against Haemophilus influenzae, MEPM had a higher activity than imipenem and flomoxef, but had a lower activity than piperacillin and cefoperazone. 2. Clinical efficacies of MEPM were evaluated in 32 cases with bacterial infections. A poor efficacy was observed in 1 patient with phlegmon but excellent or good efficacies were obtained in other 31 patients with tonsillitis (1), pneumonia (17), UTI (12), or SSSS (1). The overall efficacy rate was 96.9%. All strains except 1 of S. aureus were eradicated by the administration of MEPM, and a high eradication rate of 95.8% (23 out of 24 strains) was obtained. 3. No side effects were obsereved in 35 evaluated cases. As abnormal laboratory test results, elevated GOT, elevated GPT, eosinophilia and neutropenia were noted in 4, 4, 4 and 2 patients, respectively. 4. Influences on blood coagulation parameters were studied. PIVKA II was elevated upon administration of MEPM in some cases, but no changes in ATT, TT, HPT or Fbg were observed during the treatment. Based on the above results, it has been concluded that MEPM is a safe and effective drug to use in the treatment of pediatric infections. The usual recommended dosage and administration should be 10 to 20 mg/kg of MEPM at a time, using intravenous drip infusion, 3 times a day.

UR - http://www.scopus.com/inward/record.url?scp=0026748229&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026748229&partnerID=8YFLogxK

M3 - Article

C2 - 1507406

AN - SCOPUS:0026748229

VL - 45

SP - 744

EP - 755

JO - The Journal of antibiotics. Ser. B

JF - The Journal of antibiotics. Ser. B

SN - 0368-2781

IS - 6

ER -